Comparing R-Bendamustine vs. R-CHOP Plus maintenance therapy as first-line systemic treatment in follicular lymphoma: A multicenter retrospective GELTAMO study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Bastos Oreiro, Mariana
• dc.contributor.author Salar Silvestre, Antonio
• dc.contributor.author Sancho, Juan Manuel
• dc.date.accessioned 2025-03-11T07:13:07Z
• dc.date.available 2025-03-11T07:13:07Z
• dc.date.issued 2024
• dc.description.abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) and R-bendamustine (R-B) are the most common frontline treatment strategies for advanced-stage follicular lymphoma (FL). After R-CHOP induction therapy, using rituximab for maintenance therapy notably improves outcomes; however, whether this can be achieved by using the same approach after R-B therapy is still being determined. This retrospective analysis compared 476 FL patients from 17 GELTAMO centers who received R-based regimens followed by rituximab maintenance therapy for untreated advanced-stage FL. The complete response rate at the end of induction was higher with R-B and relapses were more frequent with R-CHOP. During induction, cytopenias were significantly more frequent with R-CHOP and so was the use of colony-stimulating factors. During maintenance therapy, R-B showed more neutropenia and infectious toxicity. After a median follow-up of 81 months (95% CI: 77-86), the 6-year rates of progression-free survival (PFS) were 79% (95% CI: 72-86) for R-bendamustine vs. 67% (95% CI: 61-73) for R-CHOP (p = 0.046), and 6-year overall survival (OS) values were 91% (95% CI: 86-96) for R-B vs. 91% (95% CI: 87-94) for R-CHOP (p = 0.49). In conclusion, R-B followed by rituximab maintenance therapy in patients with previously untreated FL resulted in significantly longer PFS than R-CHOP, with older patients also benefiting from this treatment without further toxicity. Adverse events during maintenance were more frequent with R-B without impacting mortality.
• dc.format.mimetype application/pdf
• dc.identifier.citation Bastos-Oreiro M, Gutierrez A, Cabero A, López J, Villafuerte P, Jiménez-Ubieto A, et al. Comparing R-Bendamustine vs. R-CHOP Plus maintenance therapy as first-line systemic treatment in follicular lymphoma: A multicenter retrospective GELTAMO study. Cancers (Basel). 2024 Mar 26;16(7):1285. DOI: 10.3390/cancers16071285
• dc.identifier.doi http://dx.doi.org/10.3390/cancers16071285
• dc.identifier.issn 2072-6694
• dc.identifier.uri http://hdl.handle.net/10230/69903
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Cancers (Basel). 2024 Mar 26;16(7):1285
• dc.rights © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword R-CHOP
• dc.subject.keyword R-bendamustine
• dc.subject.keyword Follicular lymphoma
• dc.subject.keyword Maintenance
• dc.subject.keyword Rituximab
• dc.title Comparing R-Bendamustine vs. R-CHOP Plus maintenance therapy as first-line systemic treatment in follicular lymphoma: A multicenter retrospective GELTAMO study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion